Clinical trial NCT05187572: Effectiveness of Reminiscence Therapy Versus Cognitive Stimulation in Older Adults With Cognitive Decline
Official title: Effectiveness of Reminiscence Therapy Versus Cognitive Stimulation in Older Adults With Cognitive Decline: a Quasi-experimental Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cognitive Decline
Lead sponsor: Escola Superior de Enfermagem de Coimbra
Sponsor class: OTHER
Collaborators: name: Junta de Freguesia de Santo António dos Olivais
name: Centro Sociocultural Polivalente de São Martinho
name: Centro Social e Paroquial de Carapinheira do Campo
name: Obra Social de Torre de Vilela
name: Centro Social Paroquial de Pedrulha
name: Associação Nacional de Apoio ao Idoso
name: Santa Casa de Misericórdia de Cantanhede
name: Doce Viver - Residencial Sénior, Bruscos
First posted: 2022-01-12
Enrollment: 106
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Although data suggest that non-pharmacologic therapies such as Reminiscence Therapy (RT) and Cognitive Stimulation (CS) can potentially maintain or reverse this trend, cognitive impairment can be a precursor to neurodegenerative processes. This study aimed to assess how an RT and a CS program affected cognition, depressive symptomatology, and quality of life (QoL) in older persons with cognitive decline who attended community support institutions in central Portugal. For seven weeks, a quasi-experimental study with two arms (RT and CS program) was conducted. The intervention was completed by 76 of the 109 older persons who were first screened (50 in the RT program, 26 in the CS program). In both groups, a pre- and post-intervention analysis revealed statistically significant differences in cognition, particularly in older adults' delayed recall ability.


Eligibility criteria: Inclusion Criteria:

* Ability to give informed consent before study commencement;
* Ability to participate in group activities for a period between 45 to 60 minutes;
* No pronounced impairment of their visual and auditory abilities;
* Mild to moderate cognitive decline, assessed as a score equal to or below 20 points in the Six-Item Cognitive Impairment Test (6-CIT).

Exclusion Criteria:

* Unstable clinical condition;
* Prescribed with cholinesterase inhibitors and/or antipsychotics during the study period.

Primary outcomes:
measure: Change in cognition (person with cognitive decline)
timeFrame: Pre-intervention (baseline)
measure: Change in depressive dymptomatology (person with cognitive decline)
timeFrame: Pre-intervention (baseline)
measure: Change in quality of life (person with cognitive decline)
timeFrame: Pre-intervention (baseline)
measure: Change in cognition (person with cognitive decline)
timeFrame: 8 weeks post baseline
measure: Change in depressive dymptomatology (person with cognitive decline)
timeFrame: 8 weeks post baseline
measure: Change in quality of life (person with cognitive decline)
timeFrame: Pre-intervention (baseline), 8 weeks post baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Coimbra
country: Portugal
facility: The Health Sciences Research Unit: Nursing
Study officials:
affiliation: Health Sciences Research Unit: Nursing, Nursing School of Coimbra
name: Rosa Silva, PhD
role: STUDY_CHAIR
affiliation: Health Sciences Research Unit: Nursing, Nursing School of Coimbra
name: João Apóstolo, PhD
role: STUDY_DIRECTOR
References: